Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13921741 | 0.83 | MEN1 (0.47) | L3MBTL1MEN1KMT2ANPSR1ANPEP | |
| SCHEMBL9910733 | 0.82 | HPGD (0.46) | L3MBTL1MEN1KMT2ANPSR1ANPEP | |
| SCHEMBL13675399 | 0.81 | POLB (0.41) | MEN1KMT2ANPSR1ANPEPLAP3 | |
| SCHEMBL20110445 | 0.80 | MEN1 (0.45) | L3MBTL1MEN1KMT2ANPSR1ANPEP | |
| SCHEMBL20110437 | 0.80 | MEN1 (0.45) | L3MBTL1MEN1KMT2ANPSR1ANPEP | |
| SCHEMBL3507159 | 0.80 | PRTN3 (0.40) | MEN1KMT2AALDH1A1RAB9AELANE | |
| SCHEMBL3507156 | 0.80 | PRTN3 (0.40) | MEN1KMT2AALDH1A1RAB9AELANE | |
| SCHEMBL30087363 | 0.79 | L3MBTL1 (0.43) | L3MBTL1MEN1KMT2ANPSR1ANPEP | |
| SCHEMBL23992573 | 0.78 | BTN3A1 (0.57) | MEN1KMT2ANPSR1ANPEPLAP3 | |
| SCHEMBL14466574 | 0.78 | BTN3A1 (0.57) | MEN1KMT2ANPSR1ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8815829-B2 | 3′-azido purine nucleotide prodrugs for treatment of viral infections | RFS PHARMA, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-05-31 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | L3MBTL1 2540/4885MEN1 2253/4885KMT2A 2934/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | L3MBTL1 2540/4885MEN1 2253/4885KMT2A 2934/4885 |
| US-20120135951-A1 | 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, ENTPD5, ADA | L3MBTL1 1504/4885MEN1 2010/4885KMT2A 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.